{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T08:46:29Z","timestamp":1778575589780,"version":"3.51.4"},"reference-count":31,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,8,14]],"date-time":"2024-08-14T00:00:00Z","timestamp":1723593600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Postmenopausal osteoporosis (PMOP) increases fracture risk in women. Though traditional treatments are slow to act, combining romosozumab with conventional therapy shows promise. Despite its growing use, studies on effectiveness are limited. This study aims to systematically evaluate the combined therapy\u2019s impact on pain relief, disease progression, and adverse reactions in PMOP patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Databases including PubMed, EMBASE, ScienceDirect, and the Cochrane Library were searched from their inception to September 2023 to identify randomized controlled trials (RCTs) evaluating the role of romosozumab in PMOP. Random or fixed effect models were employed for statistical analysis. Two reviewers independently assessed the quality of the included studies and extracted the data. The meta-analysis was conducted using RevMan 5.4 software.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Six RCTs with a total sample size of 17,985 cases were included. The incidence of vertebral fractures was compared and analyzed after 12 and 24\u2009months of treatment. Romosozumab significantly reduced the incidence of vertebral fractures at 24\u2009months (OR\u2009=\u20090.36; 95% CI: 0.35\u20130.52) but not at 12\u2009months (OR\u2009=\u20090.39; 95% CI: 0.14\u20131.05). It was also associated with a decreased incidence of nonvertebral fractures (OR\u2009=\u20090.79; 95% CI: 0.66\u20130.94) and clinical fractures at 24\u2009months (OR\u2009=\u20090.70; 95% CI: 0.59\u20130.82) compared to standard therapy. Romosozumab demonstrated a significant improvement in percentage change in bone mineral density (BMD) [mean difference (MD)\u2009=\u200910.38; 95% CI: 4.62\u201316.14] and in hip joint BMD (MD\u2009=\u20094.24; 95% CI: 2.92\u20135.56). There was no notable difference in adverse reactions compared to standard care (<jats:italic>p<\/jats:italic>\u2009&amp;gt;\u20090.05). Funnel plots displayed a predominantly symmetrical pattern, suggesting no evidence of publication bias in the selected literature.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Combining romosozumab with conventional therapy effectively treats PMOP, significantly reducing vertebral, non-vertebral, and clinical fractures while increasing BMD in the hip, femoral neck, and lumbar spine. However, further high-quality studies are needed for validation.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fmed.2024.1440948","type":"journal-article","created":{"date-parts":[[2024,8,14]],"date-time":"2024-08-14T05:03:50Z","timestamp":1723611830000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["Effects of romosozumab combined with routine therapy on pain relief, disease progression and adverse reactions in patients with postmenopausal osteoporosis: a systematic review and meta-analysis"],"prefix":"10.3389","volume":"11","author":[{"given":"Ge","family":"Gao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jian","family":"Cui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuanyuan","family":"Xie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Dong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2024,8,14]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.ecl.2021.03.009","article-title":"Postmenopausal osteoporosis: latest guidelines","volume":"50","author":"Arceo-Mendoza","year":"2021","journal-title":"Endocrinol Metab Clin N Am"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1097\/GME.0000000000001831","article-title":"Management of osteoporosis in postmenopausal women: the 2021 position statement of The North American Menopause Society","volume":"28","year":"2021","journal-title":"Menopause"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1177\/1759720X17732562","article-title":"Critical issues and current challenges in osteoporosis and fracture prevention. An overview of unmet needs","volume":"9","author":"Lems","year":"2017","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"e2121106","DOI":"10.1001\/jamanetworkopen.2021.21106","article-title":"Prevalence of osteoporosis and fracture in China: the China osteoporosis prevalence study","volume":"4","author":"Wang","year":"2021","journal-title":"JAMA Netw Open"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1007\/s11914-021-00663-1","article-title":"Anabolic agents for postmenopausal osteoporosis: how do you choose?","volume":"19","author":"Cosman","year":"2021","journal-title":"Curr Osteoporos Rep"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1186\/s12889-016-3712-7","article-title":"Prevalence of osteoporosis in China: a meta-analysis and systematic review","volume":"16","author":"Chen","year":"2016","journal-title":"BMC Public Health"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1001\/jama.2020.2923","article-title":"Bisphosphonates for postmenopausal osteoporosis","volume":"325","author":"Ensrud","year":"2021","journal-title":"JAMA"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00198-021-06095-y","article-title":"A systematic review and meta-analysis of efficacy and safety of romosozumab in postmenopausal osteoporosis","volume":"33","author":"Singh","year":"2022","journal-title":"Osteoporos Int"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"11801","DOI":"10.1038\/s41598-021-91248-6","article-title":"Denosumab versus romosozumab for postmenopausal osteoporosis treatment","volume":"11","author":"Kobayakawa","year":"2021","journal-title":"Sci Rep"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"544","DOI":"10.3803\/EnM.2021.301","article-title":"Long-term treatment of postmenopausal osteoporosis","volume":"36","author":"Brown","year":"2021","journal-title":"Endocrinol Metab"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1186\/s13018-021-02678-x","article-title":"Effect of drugs on bone mineral density in postmenopausal osteoporosis: a Bayesian network meta-analysis","volume":"16","author":"Migliorini","year":"2021","journal-title":"J Orthop Surg Res"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1186\/s12967-023-04563-z","article-title":"Romosozumab in osteoporosis: yesterday, today and tomorrow","volume":"21","author":"Wu","year":"2023","journal-title":"J Transl Med"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"1733","DOI":"10.2147\/IJWH.S315184","article-title":"Clinical utility of romosozumab in the management of osteoporosis: focus on patient selection and perspectives","volume":"14","author":"Lim","year":"2022","journal-title":"Int J Womens Health"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1056\/NEJMoa1607948","article-title":"Romosozumab treatment in postmenopausal women with osteoporosis","volume":"375","author":"Cosman","year":"2016","journal-title":"N Engl J Med"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.1016\/S0140-6736(17)31613-6","article-title":"Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: a randomised, open-label, phase 3 trial","volume":"390","author":"Langdahl","year":"2017","journal-title":"Lancet"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.bone.2017.07.005","article-title":"Romosozumab increases bone mineral density in postmenopausal Japanese women with osteoporosis: a phase 2 study","volume":"103","author":"Ishibashi","year":"2017","journal-title":"Bone"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1056\/NEJMoa1708322","article-title":"Romosozumab or alendronate for fracture prevention in women with osteoporosis","volume":"377","author":"Saag","year":"2017","journal-title":"N Engl J Med"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1056\/NEJMoa1305224","article-title":"Romosozumab in postmenopausal women with low bone mineral density","volume":"370","author":"McClung","year":"2014","journal-title":"N Engl J Med"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1002\/jbmr.3427","article-title":"FRAME study: the foundation effect of building bone with 1 year of romosozumab leads to continued lower fracture risk after transition to denosumab","volume":"33","author":"Cosman","year":"2018","journal-title":"J Bone Miner Res"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"2271","DOI":"10.1007\/s00198-020-05497-8","article-title":"Is there a role for menopausal hormone therapy in the management of postmenopausal osteoporosis?","volume":"31","author":"Rozenberg","year":"2020","journal-title":"Osteoporos Int"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"2103","DOI":"10.1007\/s00198-020-05294-3","article-title":"Determinants of imminent fracture risk in postmenopausal women with osteoporosis","volume":"31","author":"Barron","year":"2020","journal-title":"Osteoporos Int"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"816","DOI":"10.2174\/1389450121666201027124947","article-title":"Post-menopausal osteoporosis and probiotics","volume":"22","author":"Huidrom","year":"2021","journal-title":"Curr Drug Targets"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1080\/13697137.2018.1433655","article-title":"Romosozumab treatment in postmenopausal women with osteoporosis: a meta-analysis of randomized controlled trials","volume":"21","author":"Liu","year":"2018","journal-title":"Climacteric"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1016\/S2213-8587(19)30255-4","article-title":"Combination denosumab and high dose teriparatide for postmenopausal osteoporosis (DATA-HD): a randomised, controlled phase 4 trial","volume":"7","author":"Tsai","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.15586\/jptcp.v26.i4.646","article-title":"Pharmacological management of osteoporosis in postmenopausal women: the current state of the art","volume":"26","author":"Gatti","year":"2019","journal-title":"J Popul Ther Clin Pharmacol"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1007\/s00198-020-05441-w","article-title":"Effects of dynamic resistance exercise on bone mineral density in postmenopausal women: a systematic review and meta-analysis with special emphasis on exercise parameters","volume":"31","author":"Shojaa","year":"2020","journal-title":"Osteoporos Int"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.3390\/nu13051609","article-title":"Botanicals in postmenopausal osteoporosis","volume":"13","author":"S\u0142upski","year":"2021","journal-title":"Nutrients"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.2147\/DDDT.S127568","article-title":"Profile of romosozumab and its potential in the management of osteoporosis","volume":"11","author":"Lim","year":"2017","journal-title":"Drug Des Devel Ther"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"2139","DOI":"10.1002\/jbmr.4409","article-title":"Romosozumab improves lumbar spine bone mass and bone strength parameters relative to alendronate in postmenopausal women: results from the active-controlled fracture study in postmenopausal women with osteoporosis at high risk (ARCH) trial","volume":"36","author":"Brown","year":"2021","journal-title":"J Bone Miner Res"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"297","DOI":"10.4140\/TCP.n.2020.297","article-title":"Romosozumab and sequential therapy in postmenopausal osteoporosis","volume":"35","author":"Slaton","year":"2020","journal-title":"Sr care Pharm"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1177\/8755122520967632","article-title":"Romosozumab: a novel agent in the treatment for postmenopausal osteoporosis","volume":"37","author":"Miller","year":"2021","journal-title":"J Pharm Technol"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2024.1440948\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,14]],"date-time":"2024-08-14T05:03:53Z","timestamp":1723611833000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2024.1440948\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,14]]},"references-count":31,"alternative-id":["10.3389\/fmed.2024.1440948"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2024.1440948","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,14]]},"article-number":"1440948"}}